Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$742000.0.

  • Guided Therapeutics' Consolidated Net Income fell 1345.57% to -$742000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 2236.17%. This contributed to the annual value of -$2.4 million for FY2024, which is 3072.51% up from last year.
  • Per Guided Therapeutics' latest filing, its Consolidated Net Income stood at -$742000.0 for Q3 2025, which was down 1345.57% from -$811000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Consolidated Net Income registered a high of $68000.0 during Q3 2021, and its lowest value of -$1.8 million during Q4 2022.
  • Moreover, its 5-year median value for Consolidated Net Income was -$677000.0 (2023), whereas its average is -$745000.0.
  • Per our database at Business Quant, Guided Therapeutics' Consolidated Net Income surged by 8467.92% in 2021 and then crashed by 172058.82% in 2022.
  • Guided Therapeutics' Consolidated Net Income (Quarter) stood at -$444000.0 in 2021, then plummeted by 306.98% to -$1.8 million in 2022, then soared by 78.64% to -$386000.0 in 2023, then crashed by 68.91% to -$652000.0 in 2024, then dropped by 13.8% to -$742000.0 in 2025.
  • Its Consolidated Net Income was -$742000.0 in Q3 2025, compared to -$811000.0 in Q2 2025 and -$427000.0 in Q1 2025.